Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNOTHERAPY

Frontline nivolumab combinations improve OS in ESCC

Nature Reviews Clinical Oncology volume 19, page 219 (2022)Cite this article

Subjects

Nivolumab monotherapy has been shown to improve overall survival (OS) in patients with previously treated advanced-stage oesophageal squamous cell carcinoma (ESCC). Newly published data from the phase III CheckMate 648 trial now demonstrate that nivolumab also improves OS when used as combination therapy in the frontline.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

Original article

  • Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022)

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Frontline nivolumab combinations improve OS in ESCC. Nat Rev Clin Oncol 19, 219 (2022). https://doi.org/10.1038/s41571-022-00608-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00608-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing